Charles Schwab Portfolio holdings
Charles Schwab Corporation, founded in 1971 by Charles R. Schwab and headquartered in Westlake, Texas, is a leading financial services firm that revolutionized retail investing by offering low-cost brokerage services. Initially disrupting the industry with discount commissions, it has grown into a powerhouse providing a wide array of services, including trading platforms, robo-advisors, retirement accounts, and banking products, managing hundreds of billions in client assets. Known for its user-friendly technology and customer-centric approach, Schwab caters to individual investors, financial advisors, and institutions, notably expanding through its 2020 acquisition of TD Ameritrade. With a mission to democratize investing, Charles Schwab remains a dominant force in the shift toward accessible, self-directed wealth management.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Moderna
MRNA
|
+$269M |
| 2 |
Amazon
AMZN
|
+$242M |
| 3 |
Apple
AAPL
|
+$215M |
| 4 |
Amgen
AMGN
|
+$212M |
| 5 |
Citizens Financial Group
CFG
|
+$193M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vanguard FTSE Emerging Markets ETF
VWO
|
+$210M |
| 2 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$195M |
| 3 |
iShares GSCI Commodity Dynamic Roll Strategy ETF
COMT
|
+$154M |
| 4 |
MXIM
Maxim Integrated Products
MXIM
|
+$127M |
| 5 |
WORK
Slack Technologies, Inc.
WORK
|
+$115M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.58% |
| 2 | Financials | 13.47% |
| 3 | Healthcare | 12.09% |
| 4 | Consumer Discretionary | 10.78% |
| 5 | Industrials | 8.88% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
TEAD
3251
Teads Holding Co
TEAD
$65.6M
| $321K | ﹤0.01% |
+21,664
| New | +$382K |
|
|
OLO
3252
DELISTED
Olo Inc
OLO
| $321K | ﹤0.01% |
10,669
+2,797
| +36% | +$99.9K |
|
3253
ACV Auctions
ACVA
$1.27B
| $320K | ﹤0.01% |
+17,855
| New | +$379K |
|
|
IMA
3254
ImageneBio Inc
IMA
$63.7M
| $320K | ﹤0.01% |
2,109
+212
| +11% | +$30.8K |
|
3255
Five Star Bancorp
FSBC
$1.15B
| $319K | ﹤0.01% |
13,312
| – | – |
|
3256
Tango Therapeutics
TNGX
$4.29B
| $315K | ﹤0.01% |
+24,311
| New | +$291K |
|
|
ORGN
3257
DELISTED
Origin Materials
ORGN
| $314K | ﹤0.01% |
+1,536
| New | +$316K |
|
3258
Skillsoft
SKIL
$84.4M
| $314K | ﹤0.01% |
+1,341
| New | +$260K |
|
3259
KALA BIO
KALA
$16.3M
| $312K | ﹤0.01% |
48
| – | – |
|
3260
Smith & Nephew
SNN
$12.6B
| $311K | ﹤0.01% |
9,043
+185
| +2% | +$7.29K |
|
3261
Fresenius Medical Care
FMS
$12.7B
| $310K | ﹤0.01% |
8,872
-197
| -2% | -$7.7K |
|
|
CLYM
3262
Climb Bio
CLYM
$795M
| $310K | ﹤0.01% |
+17,224
| New | +$356K |
|
|
CNVY
3263
DELISTED
Convey Health Solutions Holdings, Inc.
CNVY
| $309K | ﹤0.01% |
+36,684
| New | +$327K |
|
3264
GT Biopharma
GTBP
$11.3M
| $308K | ﹤0.01% |
1,522
-411
| -21% | -$124K |
|
|
TRML
3265
DELISTED
Tourmaline Bio
TRML
| $304K | ﹤0.01% |
2,241
| – | – |
|
3266
Xponential Fitness
XPOF
$204M
| $303K | ﹤0.01% |
+23,864
| New | +$277K |
|
3267
Arq
ARQ
$97.4M
| $303K | ﹤0.01% |
47,278
| – | – |
|
|
ME
3268
DELISTED
23andMe Holding Co
ME
| $302K | ﹤0.01% |
+1,666
| New | +$296K |
|
|
CSPR
3269
DELISTED
Casper Sleep Inc.
CSPR
| $300K | ﹤0.01% |
70,042
-105,968
| -60% | -$634K |
|
3270
Biglari Holdings Class B
BH
$1.2B
| $296K | ﹤0.01% |
1,721
-4,743
| -73% | -$798K |
|
|
CLPR
3271
Clipper Realty
CLPR
$47M
| $296K | ﹤0.01% |
36,464
+6,164
| +20% | +$50.2K |
|
3272
Vera Therapeutics
VERA
$2.17B
| $295K | ﹤0.01% |
+16,948
| New | +$303K |
|
3273
Mirum Pharmaceuticals
MIRM
$5.99B
| $293K | ﹤0.01% |
14,696
-60,722
| -81% | -$988K |
|
|
SMED
3274
DELISTED
Sharps Compliance Corp
SMED
| $292K | ﹤0.01% |
35,240
| – | – |
|
3275
Avalo Therapeutics
AVTX
$1.04B
| $290K | ﹤0.01% |
46
-6
| -12% | -$48.6K |
|
Similar funds
Charles Schwab's Q3 2021 Portfolio in Review
As of Q3 2021, Charles Schwab held 3,610 positions worth $306B, up 1.6% from $301B the previous quarter. Its ten largest holdings account for 17% of the portfolio.
Charles Schwab's Q3 2021 filing shows 202 new, 2,185 increased, 922 reduced and 109 closed positions. Its largest new stake was iShares Core 1-5 Year USD Bond ETF: 3,548,215 shares worth $181M. The largest sale was Vanguard FTSE Emerging Markets ETF, an estimated $210M.
By sector, the portfolio is most concentrated in Technology at 21% of assets, up from 20% a quarter earlier, followed by Financials and Healthcare.
- Charles Schwab's largest Q3 2021 buy was iShares Core 1-5 Year USD Bond ETF: 3,548,215 shares worth $181M.
- Charles Schwab added most to Moderna in Q3 2021, an estimated $269M increase.
- Charles Schwab's biggest Q3 2021 reduction was Vanguard FTSE Emerging Markets ETF, cutting an estimated $210M.
- Charles Schwab fully exited Alexion Pharmaceuticals in Q3 2021, selling an estimated $195M.
- Charles Schwab's ten largest holdings make up 17% of its $306B portfolio in Q3 2021.
- Charles Schwab opened 202 new positions and closed 109 in Q3 2021.
- Charles Schwab's portfolio value rose 1.6% quarter-over-quarter to $306B.
Based on Charles Schwab's 13F filing for Q3 2021, filed 16 Nov 2021.